Recent Research Analysts’ Ratings Changes for Alphatec (ATEC)

Alphatec (NASDAQ: ATEC) has recently received a number of price target changes and ratings updates:

• 8/5/2026 – Alphatec had its price target raised by TD Cowen from $11.00 to $13.00. They now have a “buy” rating on the stock.
• 8/5/2026 – Alphatec had its price target raised by UBS Group AG from $15.00 to $16.00. They now have a “buy” rating on the stock.
• 8/5/2026 – Alphatec had its price target raised by BMO Capital Markets from $11.00 to $12.00. They now have an “outperform” rating on the stock.
• 8/3/2026 – Alphatec had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/28/2026 – Alphatec is now covered by UBS Group AG. They set a “buy” rating and a $15.00 price target on the stock.
• 7/28/2026 – Alphatec is now covered by UBS Group AG. They set a “buy” rating and a $15.00 price target on the stock.
• 7/23/2026 – Alphatec is now covered by Stephens. They set an “overweight” rating and a $15.00 price target on the stock.
• 7/23/2026 – Alphatec is now covered by Stephens. They set an “overweight” rating and a $15.00 price target on the stock.
• 7/23/2026 – Alphatec is now covered by Stephens. They set an “overweight” rating and a $15.00 price target on the stock.
• 7/12/2026 – Alphatec was downgraded by Wall Street Zen from “buy” to “hold”.
• 7/8/2026 – Alphatec is now covered by BMO Capital Markets. They set an “outperform” rating and a $11.00 price target on the stock.
• 7/8/2026 – Alphatec was upgraded by BMO Capital Markets to “strong-buy”.
• 7/8/2026 – Alphatec had its price target lowered by Stifel Nicolaus from $16.00 to $13.00. They now have a “buy” rating on the stock.

Insiders Place Their Bets

In other news, Director Karen K. Mcginnis sold 6,050 shares of the stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $8.01, for a total value of $48,460.50. Following the completion of the transaction, the director owned 94,671 shares in the company, valued at $758,314.71. This trade represents a 6.01% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel Tyson Eliot Marshall sold 8,168 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $9.65, for a total transaction of $78,821.20. Following the completion of the sale, the general counsel owned 630,398 shares of the company’s stock, valued at $6,083,340.70. This trade represents a 1.28% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 13.48% of the stock is currently owned by company insiders.

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.